You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 264 No. 2, July 11, 1990 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Brief Report
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (49)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Rechallenge With Crystalline Niacin After Drug-Induced Hepatitis From Sustained-Release Niacin

Yaakov Henkin, MD; Karen C. Johnson, MD, MPH; Jere P. Segrest, MD, PhD

JAMA. 1990;264(2):241-243.


Abstract

Niacin (nicotinic acid) is available in several forms, including crystalline preparations and various types of sustained-release preparations. Evidence exists that sustained-release niacin, with respect to both dosage and severity, is more hepatotoxic than crystalline niacin. Three patients who developed hepatitis during treatment with sustained-release niacin were rechallenged with equivalent or higher doses of crystalline niacin, with no evidence of recurring hepatocellular damage. Although the mechanism for niacin-induced hepatitis is unknown, these cases support previous observations that crystalline niacin may be less hepatotoxic than sustained-release preparations in certain patients.

(JAMA. 1990;264:241-243)



Author Affiliations

From the Department of Medicine, the Division of General and Preventive Medicine (Dr Henkin), the Division of Gerontology and Geriatric Medicine (Dr Segrest), and the Atherosclerosis Research Unit (Drs Henkin and Segrest), University of Alabama at Birmingham; and the Department of Preventive Medicine, Johns Hopkins University, Baltimore, Md (Dr Johnson).


Footnotes

Reprint requests to Atherosclerosis Research Unit, Department of Medicine, University of Alabama School of Medicine, UAB Station, Room 630 BDB, Birmingham, AL 35294 (Dr Segrest).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adverse Reaction to a Dietary Supplement in an Elderly Patient
Sleeper and Kennedy
The Annals of Pharmacotherapy 2003;37:83-86.
ABSTRACT | FULL TEXT  

A Comparison of the Efficacy and Toxic Effects of Sustained- vs Immediate-Release Niacin in Hypercholesterolemic Patients
McKenney et al.
JAMA 1994;271:672-677.
ABSTRACT  

Niacin-Induced Clotting Factor Synthesis Deficiency With Coagulopathy
Dearing et al.
Arch Intern Med 1992;152:861-863.
ABSTRACT  

All Niacin Is Not the Same
Frost
ANN INTERN MED 1991;114:1065-1065.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.